Form 4: Neogenomics Director Kanovsky Reports Stock Option and Restricted Stock Unit Acquisition
SEC Form 4
Director Stephen M Kanovsky reports acquisition of stock options and restricted stock units in Neogenomics Inc.
Summary
- On June 4, 2024, Stephen M Kanovsky, a director of Neogenomics Inc., filed a Form 4 with the SEC.
- The report details the acquisition of 8,672 stock options (right to buy) at an exercise price of $13.71, exercisable from June 1, 2025, and expiring on June 1, 2034.
- Kanovsky also acquired 12,254 restricted stock units, vesting from June 1, 2025.
- Following these transactions, Kanovsky directly owns 4,269 stock options exercisable at $22.52 expiring on 06/06/2026, 3,448 stock options exercisable at $28.54 expiring on 05/28/2027, 3,714 stock options exercisable at $40.9 expiring on 06/02/2028, 13,882 stock options exercisable at $8.1 expiring on 06/10/2029, 8,353 stock options exercisable at $14.82 expiring on 08/10/2033, 8,672 stock options exercisable at $13.71 expiring on 06/01/2034, 11,336 restricted stock units, and 12,254 restricted stock units.
- Kanovsky also directly owns 24,754 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, which can be interpreted as a sign of confidence, but doesn't provide definitive positive or negative information.
Positives
- The acquisition of stock options and restricted stock units by a director could be interpreted as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The filing provides shareholders with information about insider transactions, which can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/06/2020 | Date of stock options exercisable at $22.52 expiring on 06/06/2026 |
| 05/28/2021 | Date of stock options exercisable at $28.54 expiring on 05/28/2027 |
| 06/02/2022 | Date of stock options exercisable at $40.9 expiring on 06/02/2028 |
| 06/10/2023 | Date of stock options exercisable at $8.1 expiring on 06/10/2029 |
| 08/10/2024 | Date of stock options exercisable at $14.82 expiring on 08/10/2033 and restricted stock units vesting |
| 06/01/2024 | Date of transaction for stock options and restricted stock units acquisition |
| 06/04/2024 | Date of Form 4 filing |
| 06/01/2025 | Date stock options and restricted stock units become exercisable/vest |
| 06/06/2026 | Expiration date of stock options exercisable at $22.52 |
| 05/28/2027 | Expiration date of stock options exercisable at $28.54 |
| 06/02/2028 | Expiration date of stock options exercisable at $40.9 |
| 06/10/2029 | Expiration date of stock options exercisable at $8.1 |
| 08/10/2033 | Expiration date of stock options exercisable at $14.82 |
| 06/01/2034 | Expiration date of stock options exercisable at $13.71 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.